Technology
Health
Biotechnology

Bellicum Pharmaceuticals

$2.36
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.05 (2.16%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell BLCM and other stocks, options, ETFs, and crypto commission-free!

About

Bellicum Pharmaceuticals, Inc. Common Stock, also called Bellicum Pharmaceuticals, is a clinical stage biopharmaceutical company, which focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Read More It uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.

Employees
173
Headquarters
Houston, Texas
Founded
2004
Market Cap
106.12M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
463.79K
High Today
$2.43
Low Today
$2.25
Open Price
$2.33
Volume
371.91K
52 Week High
$10.26
52 Week Low
$2.25

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
2014 IPO
US

News

Yahoo FinanceMay 7

Bellicum Pharmaceuticals (BLCM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

290
Yahoo FinanceMay 7

Bellicum Pharmaceuticals (BLCM) Reports Q1 Loss, Tops Revenue Estimates

Bellicum Pharmaceuticals (BLCM) delivered earnings and revenue surprises of 1.79% and 158.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

124
Yahoo FinanceMay 7

Bellicum Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Operational Update

Interim data for BPX-601 accepted for presentation at upcoming American Society of Clinical Oncology (ASCO) Annual Meeting Rivo-cel™ on-track for topline data readout from BP-004 pediatric trial in second quarter of 2019 HOUSTON, May 07, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the first quarter 2019 and provided an operational u...

19

Earnings

-$0.74
-$0.68
-$0.61
-$0.55
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 6, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.